Technical Analysis for MLNT - Melinta Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 4.28 -2.28% -0.10
MLNT closed down 2.28 percent on Friday, October 18, 2019, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Earnings due: Nov 5

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical MLNT trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup -2.28%
Upper Bollinger Band Walk Strength -2.28%
Inside Day Range Contraction -2.28%
Wide Bands Range Expansion -2.28%
Overbought Stochastic Strength -2.28%

Older signals for MLNT ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Melinta Therapeutics, Inc., formerly Cempra, Inc., is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus and other gram-positive bacteria.
Medical Specialties Pharmaceutical Infectious Diseases Antibiotics Microbiology Healthcare Associated Infections Bacterial Diseases Pathogenic Bacteria Staphylococcus Aureus Community Acquired Bacterial Pneumonia
Is MLNT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 19.3
52 Week Low 1.62
Average Volume 398,544
200-Day Moving Average 4.222
50-Day Moving Average 3.0904
20-Day Moving Average 3.8015
10-Day Moving Average 3.929
Average True Range 0.3561
ADX 32.13
+DI 32.872
-DI 21.474
Chandelier Exit (Long, 3 ATRs ) 3.6817
Chandelier Exit (Short, 3 ATRs ) 4.0283
Upper Bollinger Band 4.4335
Lower Bollinger Band 3.1695
Percent B (%b) 0.88
BandWidth 33.250033
MACD Line 0.2988
MACD Signal Line 0.2354
MACD Histogram 0.0635
Fundamentals Value
Market Cap 224.74 Million
Num Shares 52.5 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -2.27
Price-to-Sales 6.92
Price-to-Book 0.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.12
Resistance 3 (R3) 5.07 4.74 4.98
Resistance 2 (R2) 4.74 4.53 4.77 4.93
Resistance 1 (R1) 4.51 4.39 4.35 4.56 4.89
Pivot Point 4.18 4.18 4.10 4.21 4.18
Support 1 (S1) 3.95 3.97 3.79 4.00 3.67
Support 2 (S2) 3.62 3.83 3.65 3.63
Support 3 (S3) 3.39 3.62 3.58
Support 4 (S4) 3.44